Will Aegerion Need Another TV Interview To Satisfy FDA After Juxtapid Citation?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks for correction in warning letter objecting to CEO statements on CNBC’s “Fast Money” that touted the rare lipid disorder treatment.
You may also be interested in...
Voice of the Patient: Peer “Ambassadors” Help Recruitment at Aegerion
In the ultra-orphan, ultra-priced segment where the recruitment of each patient is a major commercial event, the voice of existing patients can be very important.
Aegerion Resolves FDA Warning About Juxtapid Promotion But DOJ Probe Continues
Corrective broadcast clarifying statements its CEO made on CNBC’s “Fast Money” produces a close-out letter, but the firm emphasizes the cost and risks of a DOJ investigation.
Voice of the Patient: Peer “Ambassadors” Help Recruitment at Aegerion
In the ultra-orphan, ultra-priced segment where the recruitment of each patient is a major commercial event, the voice of existing patients can be very important.